Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion
The American Journal of Surgery Aug 10, 2018
Qi YP, et al. - Researchers compared outcomes of patients with hepatocellular carcinoma (HCC) involving microvascular invasion (MVI) receiving adjuvant transarterial chemoembolization (A-TACE) after hepatic resection (HR) vs HR alone. This study included 200 consecutive patients with MVI-HCC who either underwent HR alone or HR with A-TACE. Using the Kaplan-Meier method, they compared disease-free survival (DFS) and overall survival (OS). The two groups were similar regarding DFS at 1, 2, and 3 years, but the A-TACE group had significantly higher OS in general, and significantly higher OS and DFS for those with tumor diameter > 5 cm or multinodular tumors.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries